Business context and reporting period
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company developing cancer and diabetes treatments using its licensed Cell-in-a-Box live-cell encapsulation technology. Its priorities include preparing pancreatic-cancer clinical trials and conducting preclinical diabetes work.
Period clarification: Although the request metadata says 2015 Q3, this 10-Q covers the three and nine months ended January 31, 2016, with comparisons to the corresponding 2015 periods. The financial statements are unaudited.
Financial results and liquidity
| Metric | Three months ended Jan. 31, 2016 | Three months ended Jan. 31, 2015 | Nine months ended Jan. 31, 2016 | Nine months ended Jan. 31, 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $1.79 million | $1.46 million | $4.94 million | $9.29 million |
| Net loss | $1.79 million | $1.46 million | $4.94 million | $7.11 million |
| Operating cash used | Not presented for quarter | Not presented for quarter | $3.13 million | $3.47 million |
With no revenue in either period, the filing reports no cost of revenue or gross margin; margin is therefore not meaningful. Nine-month 2016 loss per share was $0.01, compared with $0.01 in 2015. Quarterly loss per share was reported as $0.00 in both periods.
At January 31, 2016, cash was $2.86 million, current assets were $2.87 million, and working capital was approximately $1.8 million. Total liabilities were $1.07 million, all current; the balance sheet shows no debt. Cash increased $164,245 over the nine months, with $3.29 million of financing proceeds, principally from common-stock sales. Total assets were $8.00 million and stockholders’ equity was $6.94 million.
Material changes and notable items
- Quarterly operating expenses increased $336,000 year over year, primarily from higher research and development and compensation costs, partly offset by lower general and administrative and legal expenses.
- Nine-month operating expenses fell $4.34 million year over year, mainly because stock-based compensation was substantially lower; the 2015 period also included a $2.18 million gain on settlement of stock recoveries that did not recur. Research and development costs increased $548,000 year over year.
- During the nine months, the company raised approximately $2.8 million net through registered common-stock sales and received $1.02 million gross from a January private placement of 17 million shares and warrants to purchase 17 million additional shares. Shares outstanding rose to 771.4 million at January 31, from 732.8 million at April 30, 2015.
- The company had 68.05 million options and 84.97 million warrants outstanding at January 31; these were excluded from diluted loss per share as anti-dilutive.
- After January 31, the company paid Austrianova $100,000 under its cannabis license and issued additional shares for approximately $45,000 gross proceeds.
Outlook, risks, and contingencies
Management said January 31 cash was expected to fund current operations and general working capital for the next 12 months, while also stating it planned to pursue additional funding for clinical-trial activities. This is not a revenue or earnings forecast, and the filing provides no quantified operating guidance.
- The company remains pre-revenue and dependent on external financing. Management warned that financing may not be available on favorable terms and could dilute shareholders. If non-affiliate public float falls below $75 million at the specified 2016 annual-report filing date, the company may lose eligibility to sell securities under its Form S-3 registration statement.
- License agreements require future milestone and royalty payments, many contingent on development progress, regulatory approvals, sales, or sublicensing. The cannabis license required a $2.0 million upfront payment; $1.7 million had been paid by January 31, with $300,000 remaining and a payment deadline extended to June 30, 2016. A manufacturing agreement for that program remained unsigned.
- Management reported disclosure controls and internal control over financial reporting were ineffective as of January 31, 2016, citing material weaknesses including ineffective governance, inadequate documentation and segregation of duties, and insufficient IT controls. The filing references prior financial-statement restatements; no material remediation changes had been made by January 31.
- The company reported no material pending legal proceedings and no material change to previously disclosed risk factors apart from the Form S-3 eligibility risk. It also reported approximately $2.61 million in cash balances above FDIC insurance limits at January 31.
Important facts for investors to verify
- Whether cash burn, planned clinical-trial spending, and the stated 12-month liquidity expectation remain consistent with available funding.
- Progress, timing, and costs for pancreatic-cancer trials and diabetes preclinical work, including required manufacturing and regulatory preparations.
- Remaining cannabis-license payments, the status of the manufacturing agreement, and potential milestone, royalty, and other license obligations.
- Share issuance, option and warrant dilution, and continued eligibility to raise capital using Form S-3.
- Remediation of disclosed control weaknesses and the accuracy of financial reporting following the referenced restatements.